SG11202004895UA - Optimised compounds - Google Patents

Optimised compounds

Info

Publication number
SG11202004895UA
SG11202004895UA SG11202004895UA SG11202004895UA SG11202004895UA SG 11202004895U A SG11202004895U A SG 11202004895UA SG 11202004895U A SG11202004895U A SG 11202004895UA SG 11202004895U A SG11202004895U A SG 11202004895UA SG 11202004895U A SG11202004895U A SG 11202004895UA
Authority
SG
Singapore
Prior art keywords
optimised
compounds
optimised compounds
Prior art date
Application number
SG11202004895UA
Inventor
David Jackson
Ian Holmes
Weiguang Zeng
Christophe Demaison
Original Assignee
Ena Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017905128A external-priority patent/AU2017905128A0/en
Application filed by Ena Therapeutics Pty Ltd filed Critical Ena Therapeutics Pty Ltd
Publication of SG11202004895UA publication Critical patent/SG11202004895UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202004895UA 2017-12-21 2018-12-21 Optimised compounds SG11202004895UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2017905128A AU2017905128A0 (en) 2017-12-21 Optimised compounds
AU2018901056A AU2018901056A0 (en) 2018-03-29 Optimised compounds (2)
AU2018903597A AU2018903597A0 (en) 2018-09-25 Optimised compounds (3)
PCT/AU2018/051397 WO2019119067A1 (en) 2017-12-21 2018-12-21 Optimised compounds

Publications (1)

Publication Number Publication Date
SG11202004895UA true SG11202004895UA (en) 2020-06-29

Family

ID=66992416

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004895UA SG11202004895UA (en) 2017-12-21 2018-12-21 Optimised compounds

Country Status (11)

Country Link
US (1) US20210230217A1 (en)
EP (1) EP3728289A4 (en)
JP (2) JP7439367B2 (en)
KR (1) KR20200101428A (en)
CN (1) CN111491943A (en)
AU (1) AU2018391325B2 (en)
BR (1) BR112020012360A2 (en)
CA (1) CA3085377A1 (en)
IL (1) IL275360B2 (en)
SG (1) SG11202004895UA (en)
WO (1) WO2019119067A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019119069A1 (en) * 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent
BR112021025630A8 (en) 2019-06-26 2023-04-11 Axelia Oncology Pty Ltd NEW MOLECULES
AU2021278377A1 (en) * 2020-05-26 2022-12-15 Ena Respiratory Pty Ltd Treatment of coronavirus
JP2023531387A (en) 2020-06-26 2023-07-24 イーナ レスパラトリー ピーティーワイ リミテッド branched lipid compounds
JP2024532434A (en) * 2021-09-02 2024-09-05 イーナ レスパラトリー ピーティーワイ リミテッド formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119759A1 (en) * 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2016037240A1 (en) * 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent
CN110461351B (en) * 2017-03-31 2024-03-26 艾娜呼吸私人有限公司 Treatment of respiratory tract infections with TLR2 agonists
WO2019119069A1 (en) * 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent

Also Published As

Publication number Publication date
EP3728289A1 (en) 2020-10-28
KR20200101428A (en) 2020-08-27
IL275360A (en) 2020-07-30
EP3728289A4 (en) 2021-10-13
IL275360B1 (en) 2023-06-01
US20210230217A1 (en) 2021-07-29
AU2018391325A1 (en) 2020-06-18
BR112020012360A2 (en) 2020-11-24
AU2018391325B2 (en) 2024-07-11
JP2024001114A (en) 2024-01-09
JP7439367B2 (en) 2024-02-28
CN111491943A (en) 2020-08-04
WO2019119067A1 (en) 2019-06-27
CA3085377A1 (en) 2019-06-27
JP2021506915A (en) 2021-02-22
IL275360B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201704327D0 (en) Compounds
GB201700814D0 (en) Compounds
GB201715342D0 (en) Compounds
PT3612519T (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
GB201704325D0 (en) Compounds
IL275360A (en) Optimised compounds
GB201713962D0 (en) Compounds
GB201716871D0 (en) Compounds
IL292485B2 (en) Pyridylpyridone compounds
GB201707938D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
AU2017905128A0 (en) Optimised compounds
GB201717050D0 (en) Compounds
GB201716688D0 (en) Compounds
GB201716352D0 (en) Compounds
GB201716374D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201713318D0 (en) Compounds